Jump to content
Frequently Asked Questions About Celiac Disease Read more... ×
  • Sign Up
0
Scott Adams

Celiac Vaccine Clears First Big Clinical Trial

Rate this topic

Recommended Posts

syringe--red--cc--andres_rueda.jpg

Massachusetts biotech firm ImmusanT has announced the successful completion of its first phase 1b trial of Nexvax2, an immunotherapy drug designed to protect celiac sufferers from the adverse effects of gluten exposure, including gastrointestinal symptoms, such as diarrhea, abdominal pain and bloating.

Nexvax2 is a drug that relies on three peptides designed to promote T cells involved in the inflammatory reaction in celiac disease to become tolerant to gluten.

The company hopes that an initial course will promote gluten-tolerance, which can then be maintained by periodic boosters of the vaccine.

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×